HCM CITY — Opella has officially launched as an independent company, following the successful closing of a transaction in which global investment firm CD&R acquired a 50 per cent controlling stake from Sanofi.

The French pharmaceutical giant retains a significant 48.2 per cent ownership, while Bpifrance holds the remaining 1.8 per cent.

As the purest and third-largest global player in the 190 billion euros (US$213.3 billion) over-the-counter and vitamins, minerals and supplements space, Opella is set to lead in one of the most dynamic, resilient corners of healthcare – where megatrends like aging populations, digital access, and self-care demand are rewriting the rulebook.

Headquartered in France, Opella operates with a global footprint. Its 100 brands – including Allegra, Dulcolax, Enterogermina or Doliprane – are already trusted names in homes around the world.

​In Việt Nam, Opella has offices in HCM City, Hà Nội, and a manufacturing site with advanced and automated technology in Saigon Hi Tech Park with Australia’s TGA and Korea’s MFDS -GMP certificates.

Việt Nam is also home to Opella’s only product research and development centre in Asia — one of the company’s four global R&D centres. Products manufactured here are exported to 13 countries.

Valentina Belcheva, General Manager of Opella Vietnam and Cambodia, said: “Việt Nam is a market of immense potential with 100 million people and growing demand for self-care. At Opella, we are acting decisively to strengthen our position by leveraging our trusted, science-backed brands and deep market expertise. Through strategic partnerships, we are driving awareness and access to make self-care as simple as it should be.” — VNS